<DOC>
	<DOCNO>NCT00004667</DOCNO>
	<brief_summary>OBJECTIVES : I . Evaluate effect new von Willebrand factor concentrate bleeding time , vivo recovery , circulate half-life infused factor patient von Willebrand 's disease . II . Assess safety von Willebrand factor patient .</brief_summary>
	<brief_title>Phase I Study Human Von Willebrand Factor Von Willebrand 's Disease</brief_title>
	<detailed_description>PROTOCOL OUTLINE : Patients receive 1 dose von Willebrand factor concentrate . Timed blood study perform next 96 hour . Patients follow every 2 week 16 week , 24 , 36 , 52 week .</detailed_description>
	<mesh_term>Von Willebrand Diseases</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : von Willebrand 's disease</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2001</verification_date>
	<keyword>hematologic disorder</keyword>
	<keyword>rare disease</keyword>
	<keyword>von Willebrand 's disease</keyword>
</DOC>